RxDoctor Payments Data

Christina Defibaugh, APRN

Psychiatric/Mental Health · Maxwelton, WVNPI 1427754837

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 27.8% of the total.

$1,660in general payments, 2019–2025

Across 97 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$462
  • Otsuka America Pharmaceutical, Inc.$359
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$262
  • Indivior Inc.$128
  • Johnson & Johnson$109
  • Neurocrine Biosciences, Inc.$106
  • plus $234 from 4 others

What the payments were for

  • Food & beverage$1,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,660 in reported general payments places this provider in the 70th percentile of 142 psychiatric/mental health providers in West Virginia.

See all psychiatric/mental health providers in West Virginia

Medicare billing

Part B allowed, 2024
$12,454
Medicare patients
61
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$110,180
VraylarCariprazine Hcl19$27,050
RexultiBrexpiprazole17$24,341
Aripiprazole31$4,103
Lurasidone Hcl20$3,165
Oxcarbazepine31$1,267
Bupropion XlBupropion Hcl95$1,232
Ziprasidone Hcl18$888
Fluvoxamine Maleate21$864
Quetiapine Fumarate74$807
Mirtazapine41$804
Fluoxetine Hcl70$706
Hydroxyzine Pamoate47$670
Trazodone Hcl94$651
Buspirone Hcl85$640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$106$110,18013 claims
AbbVieVraylar$462$27,05019 claims
Otsuka America Pharmaceutical, Inc.Rexulti$359$24,34117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 142 psychiatric/mental health providers in West Virginia.

Other psychiatric/mental health in Maxwelton

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →